{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.136","upperLimit":"0.618","value":"0.377"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"}],"units":"Participants"}],"description":"The Youden Index will be used to determine the optimal threshold for PD-L1 expression in correlation with tumor response. Youden Index ranges from 0-1 with higher scores meaning greater accuracy/sensitivity/specificity calculated from an ROC AUC (sensitivity + specificity - 1 = Youden Index).","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients may be eligible for up to 1 year of additional pembrolizumab therapy if they progress after stopping pembrolizumab.\n\nPembrolizumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacogenomic Study: Correlative studies","id":"OG000","title":"Treatment (Pembrolizumab)"}],"paramType":"NUMBER","populationDescription":"Two patients had missing PD-L1 expression data.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Ability of PD-L1 to Predict Response","type":"PRIMARY","unitOfMeasure":"Youden index"}